Hero Image

How Doctors Evaluate Lung Nodules: Tests and Timing

Hearing you have a lung nodule can feel unsettling, but most nodules are not cancer.

The good news: doctors follow a clear, evidence-based pathway to figure out what the spot is, how risky it might be, and whether it needs monitoring, more imaging, or a biopsy.

What Is a Lung Nodule?

A lung (pulmonary) nodule is a small, round or oval area of denser tissue in the lung that measures 30 millimeters (about 1.2 inches) or less. Anything larger is typically called a lung mass and is evaluated more aggressively. Nodules are common and are often found by accident on a chest X-ray or CT scan done for another reason. In non-smokers and in nodules under about 8–10 mm, the chance of cancer is low—often well under 5%.

Benign causes are far more frequent than malignant ones. Old infections (for example, tuberculosis or histoplasmosis), inflammatory conditions such as sarcoidosis, and non-cancerous growths like hamartomas are common explanations. Reliable patient overviews, like those from the American Thoracic Society, can help you understand why most nodules turn out to be harmless.

The First Look: What Radiologists Assess

When a nodule shows up on CT, radiologists evaluate a handful of features that strongly predict cancer risk. These characteristics guide whether you simply return for a follow-up scan or move on to more advanced testing.

1) Size matters

Size is one of the strongest predictors of risk, and it informs guideline-based follow-up (for example, the widely used Fleischner Society recommendations for incidentally found nodules in adults):

  • Under 6 mm: Very low risk in most people, especially non-smokers; often no immediate follow-up is needed.
  • 6–8 mm: Usually merits a repeat CT in about 6–12 months to check for growth.
  • Over 8 mm: Closer monitoring is warranted; doctors may consider a shorter-interval CT, PET-CT, and/or biopsy depending on other risk factors.

2) Shape and edges

The border of a nodule tells a story. Smooth, well-defined nodules are more often benign. Irregular, lobulated, or spiculated (spiky) edges raise suspicion because they can signal growth that infiltrates nearby tissue.

3) Density and composition

On CT, some nodules are solid (uniformly dense), while others are subsolid, such as ground-glass nodules (hazy) or part-solid nodules (a mix of ground-glass and solid). Part-solid nodules, in particular, carry a higher chance of malignancy and need closer follow-up. Certain calcification patterns—central, diffuse, or “popcorn” calcifications—are reassuring and often point to benign causes like hamartomas. Learn more about ground-glass nodules here: ground-glass nodules on CT.

4) Growth over time

Watching how a nodule changes is one of the most reliable ways to determine risk. A common approach is “active surveillance,” repeating CT scans over months to years to see if the nodule grows.

  • No growth: A solid nodule that stays the same size for about two years is usually considered benign.
  • Slow, steady growth: Concerning and typically prompts advanced imaging and/or biopsy.
  • Very rapid growth: More suggestive of infection or inflammation than cancer.

Subsolid nodules (especially part-solid ones) can require longer observation—sometimes up to five years—because certain slow-growing cancers evolve over time.

Advanced Tests When Suspicion Is Higher

When a nodule is larger, has suspicious features, or grows over time, your clinician will move beyond surveillance to gather more information.

High-resolution and contrast-enhanced CT

Follow-up CT may use thin slices for finer detail and, in some cases, an intravenous contrast dye. Nodules that enhance substantially with contrast can be more suspicious because malignant tissue often has a richer blood supply.

PET-CT (positron emission tomography–computed tomography)

For nodules roughly 8 mm and larger, a PET-CT can help assess metabolic activity. Before the scan, you receive a small amount of radioactive sugar; cancer cells tend to consume more sugar and may “light up” on the images. Inflammation and infection can also cause uptake, so PET results are interpreted alongside CT findings and your clinical history.

Risk models and clinical context

Doctors combine imaging features with your age, smoking history, exposures (e.g., radon or asbestos), and medical history to estimate the probability of cancer. Validated tools, such as the Brock model (risk calculator), can support shared decision-making about whether to watch, scan with PET-CT, or sample the nodule.

Getting Tissue: Biopsy Options

The only definitive way to diagnose cancer is by examining tissue under a microscope. Your team will choose a biopsy method based on the nodule’s size, location, and your overall health.

Bronchoscopy (including navigational and ultrasound-guided)

A pulmonologist passes a thin, flexible scope through the mouth or nose into the airways to reach the nodule and collect tiny samples. For deeper or smaller lesions, tools like radial endobronchial ultrasound (EBUS) or electromagnetic navigation improve accuracy. Learn about bronchoscopy from the American Lung Association. Complications are uncommon and usually mild (e.g., temporary sore throat or small amounts of bleeding).

CT-guided needle biopsy (transthoracic needle aspiration)

For nodules near the outer lung, a radiologist can guide a fine needle through the chest wall under CT imaging to retrieve cells or tissue. This approach has a high diagnostic yield for peripheral nodules. The most common risk is a small air leak (pneumothorax); many are minor, but a subset may need a temporary chest tube. See a patient-friendly overview of risks and benefits here: lung biopsy.

Surgical removal (video-assisted thoracoscopic surgery, VATS)

When probability of cancer is high—or other methods are unlikely to succeed—surgeons may remove the nodule using minimally invasive techniques. With VATS, small incisions and a camera allow surgeons to both diagnose and, if appropriate, fully treat early-stage cancers in the same procedure.

Follow-Up Timelines: What Real Cases Look Like

Exact timing depends on your risk profile and whether the nodule was found during routine screening or incidentally. Screening programs often use Lung-RADS categories, while incidental nodules often follow Fleischner guidance. People at increased risk (e.g., long-term smokers) may also qualify for annual low-dose CT screening per the USPSTF.

  • Scenario 1: A 5 mm smooth solid nodule in a non-smoker. Plan: often no immediate follow-up; some clinicians offer a 12-month CT for reassurance.
  • Scenario 2: A 7 mm solid nodule in a former smoker. Plan: repeat CT in 6–12 months; if unchanged, another CT at 18–24 months may be advised.
  • Scenario 3: A 12 mm spiculated part-solid nodule. Plan: prompt PET-CT and consideration of biopsy or surgical referral depending on PET uptake and overall risk.

Remember, these are examples; your doctor will tailor recommendations to your imaging features and personal risk factors.

Frequently Asked Questions

Are most lung nodules cancer?

No. Most are benign—especially in people with small nodules, no smoking history, and reassuring imaging features.

How long until I know if a nodule is serious?

For very low-risk nodules, confirmation that it’s harmless often comes after stable imaging over about two years (longer for some subsolid nodules). If a nodule looks suspicious, doctors move faster with PET-CT and biopsy, and you may have answers within a few weeks.

Do lung nodules cause symptoms?

Usually not. Most are too small to cause cough, pain, or shortness of breath and are found incidentally on imaging done for other reasons.

Should I seek a second opinion?

Absolutely. Complex or anxiety-provoking findings are good reasons to have another specialist review your images, risks, and options.

Key Takeaways

  • Most lung nodules are benign, particularly when small and smooth.
  • Risk assessment hinges on size, edges, density, and growth over time.
  • Advanced tools—contrast CT, PET-CT, and biopsies—are used selectively.
  • Shared decision-making, often supported by risk calculators, guides next steps.

If you’ve been told you have a lung nodule, ask your clinician which guideline they’re using (Fleischner or Lung-RADS), your estimated cancer risk, and the specific plan for follow-up or testing. Knowing the rationale behind each step can bring clarity and peace of mind.